RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Enhancing clarity of clinical trial safety reports for data monitoring committees
Thomas, S. M., Jung, K., Sun, H., Psioda, M. A., Quibrera, P. M., & Strakowski, S. M. (2020). Enhancing clarity of clinical trial safety reports for data monitoring committees. Journal of Biopharmaceutical Statistics, 30(6), 1147-1161. https://doi.org/10.1080/10543406.2020.1815034
A Data Monitoring Committee (DMC) evaluates patient safety in a clinical trial of an investigational intervention through periodic review of adverse events (AEs) and clinical safety assessments. Our aim was to construct DMC report displays to enhance the DMC safety review through use of graphics and clear identification and adjustment for missing data caused by early discontinuations and ongoing study participation. Suggested displays include a study snapshot graph, enhanced adverse event incidence tables including the incidence density and plotted incidence proportions, line graphs in place of by-patient listings, and trend plots in place of tables for continuous assessments.